Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
Andersen CF, Larsen JH, Jensen J, Omar M, Nouhravesh N, Kistorp C, Tuxen C, Gustafsson F, Knop FK, Forman JL, Davidovski FS, Jensen LT, Højlund K, Køber L, Antonsen L, Poulsen MK, Schou M, Møller JE. Andersen CF, et al. Among authors: larsen jh. Am Heart J. 2024 May;271:84-96. doi: 10.1016/j.ahj.2024.02.005. Epub 2024 Feb 15. Am Heart J. 2024. PMID: 38365073 Free article.
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Omar M, Jensen J, Kistorp C, Højlund K, Videbæk L, Tuxen C, Larsen JH, Andersen CF, Gustafsson F, Køber L, Schou M, Møller JE. Omar M, et al. Among authors: larsen jh. Cardiovasc Diabetol. 2022 Feb 27;21(1):34. doi: 10.1186/s12933-022-01463-2. Cardiovasc Diabetol. 2022. PMID: 35219331 Free PMC article. Clinical Trial.
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial.
Jensen J, Omar M, Ali M, Frederiksen PH, Kistorp C, Tuxen C, Andersen CF, Larsen JH, Ersbøll MK, Køber L, Gustafsson F, Faber J, Forman JL, Møller JE, Schou M. Jensen J, et al. Among authors: larsen jh. Am Heart J. 2022 Aug;250:57-65. doi: 10.1016/j.ahj.2022.04.008. Epub 2022 May 2. Am Heart J. 2022. PMID: 35513022 Free article. Clinical Trial.
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial.
Larsen JH, Omar M, Jensen J, Andersen CF, Kistrup CM, Poulsen MK, Videbæk L, Gustafsson F, Køber L, Schou M, Møller JE. Larsen JH, et al. Am Heart J Plus. 2023 Feb 3;26:100264. doi: 10.1016/j.ahjo.2023.100264. eCollection 2023 Feb. Am Heart J Plus. 2023. PMID: 38510180 Free PMC article.
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status.
Fuchs Andersen C, Omar M, Larsen JH, Kistorp C, Tuxen C, Gustafsson F, Køber L, Poulsen MK, Brønd JC, Møller JE, Schou M, Jensen J. Fuchs Andersen C, et al. Among authors: larsen jh. Am Heart J. 2024 Dec;278:14-23. doi: 10.1016/j.ahj.2024.08.017. Epub 2024 Aug 30. Am Heart J. 2024. PMID: 39209211 Free article. Clinical Trial.
Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosis.
Larsen JH, Hegelund JS, Pedersen MK, Andersson CM, Lindegaard CA, Hansen DR, Stubbe J, Lindholt JS, Hansen CS, Grentzmann A, Bloksgaard M, Jensen BL, Rodriguez-Díez RR, Ruiz-Ortega M, Albinsson S, Pasterkamp G, Mokry M, Leask A, Goldschmeding R, Pilecki B, Sorensen GL, Pyke C, Overgaard M, Beck HC, Ketelhuth DFJ, Rasmussen LM, Steffensen LB. Larsen JH, et al. Cardiovasc Res. 2024 Dec 4;120(15):1851-1868. doi: 10.1093/cvr/cvae174. Cardiovasc Res. 2024. PMID: 39167826 Free PMC article.
104 results